GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Diagnostics & Research » BCAL Diagnostics Ltd (ASX:BDX) » Definitions » PS Ratio

BCAL Diagnostics (ASX:BDX) PS Ratio : (As of Jun. 06, 2024)


View and export this data going back to 2021. Start your Free Trial

What is BCAL Diagnostics PS Ratio?

The PS Ratio, or Price-to-Sales ratio, or Price/Sales, is a financial ratio used to compare a company's market price to its Revenue per Share. As of today, BCAL Diagnostics's share price is A$0.125. BCAL Diagnostics's Revenue per Share for the trailing twelve months (TTM) ended in Dec. 2023 was A$0.00. Hence, BCAL Diagnostics's PS Ratio for today is .

The historical rank and industry rank for BCAL Diagnostics's PS Ratio or its related term are showing as below:

ASX:BDX's PS Ratio is not ranked *
in the Medical Diagnostics & Research industry.
Industry Median: 3.19
* Ranked among companies with meaningful PS Ratio only.

BCAL Diagnostics's Revenue per Sharefor the six months ended in Dec. 2023 was A$0.00. Its Revenue per Share for the trailing twelve months (TTM) ended in Dec. 2023 was A$0.00.

Back to Basics: PS Ratio


BCAL Diagnostics PS Ratio Historical Data

The historical data trend for BCAL Diagnostics's PS Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

BCAL Diagnostics PS Ratio Chart

BCAL Diagnostics Annual Data
Trend Jun22 Jun23
PS Ratio
- -

BCAL Diagnostics Semi-Annual Data
Dec20 Dec21 Jun22 Dec22 Jun23 Dec23
PS Ratio Get a 7-Day Free Trial - - - - -

Competitive Comparison of BCAL Diagnostics's PS Ratio

For the Diagnostics & Research subindustry, BCAL Diagnostics's PS Ratio, along with its competitors' market caps and PS Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


BCAL Diagnostics's PS Ratio Distribution in the Medical Diagnostics & Research Industry

For the Medical Diagnostics & Research industry and Healthcare sector, BCAL Diagnostics's PS Ratio distribution charts can be found below:

* The bar in red indicates where BCAL Diagnostics's PS Ratio falls into.



BCAL Diagnostics PS Ratio Calculation

The PS Ratio, or Price-to-Sales ratio, or Price/Sales, is a financial ratio used to compare a company's market price to its Revenue per Share. It is a ratio widely used to value stocks and it was first used by Ken Fisher.

BCAL Diagnostics's PS Ratio for today is calculated as

PS Ratio=Share Price/Revenue per Share (TTM)
=0.125/0
=

BCAL Diagnostics's Share Price of today is A$0.125.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. BCAL Diagnostics's Revenue per Share for the trailing twelve months (TTM) ended in Dec. 2023 was A$0.00.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

It can also be calculated from the numbers for the whole company:

PS Ratio=Market Cap/Revenue

The Revenue here is for the trailing 12 months.


BCAL Diagnostics  (ASX:BDX) PS Ratio Explanation

The PS Ratio is an excellent valuation indicator if you want to compare a stock with its historical valuation or with the stocks in the same industry. The PS Ratio works especially well when you want to compare the stock's current valuation with its historical valuation. The PS Ratio is a great valuation tool for evaluating cyclical businesses where the PE Ratio works poorly. It works the best when comparing the current valuation with the historical valuation because over time, a company's profit margin tends to revert to the mean.

When the PS Ratio is applied to the whole stock market, it can be used to evaluate the current market valuation and projected returns. In this case, the price is the total market cap of all stocks that are traded, and sales are the GDP of the country. This is how Warren Buffett estimates the broad market valuation and project future returns.

Similar to the PE Ratio or Price-to-Operating-Cash-Flow or Price-to-Free-Cash-Flow , the PS Ratio measures the valuation based on the earning power of the company. This is where it is different from the PB Ratio , which measures the valuation based on the company's balance sheet.


Be Aware

The PS Ratio does not tell you how cheap or expensive the stock is. It cannot be used to compare companies in different industries. It works better for companies within the same industry because these companies tend to have similar capital structures and profit margins. It works the best when comparing a company with itself in the past.


BCAL Diagnostics PS Ratio Related Terms

Thank you for viewing the detailed overview of BCAL Diagnostics's PS Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


BCAL Diagnostics (ASX:BDX) Business Description

Traded in Other Exchanges
N/A
Address
Queen Victoria Building, GPO Box Q128, Sydney, NSW, AUS, 1230
BCAL Diagnostics Ltd is a biotechnology company developing a novel blood screening test to improve the early diagnosis and monitoring of breast cancer by identifying, measuring, and validating specific biomarkers enriched from patient's blood. The BCAL technology utilizes a single blood test on multiple levels including disease detection, diagnostic mass screening, and post-intervention.

BCAL Diagnostics (ASX:BDX) Headlines